Video

Dr. Wei on the Efficacy of Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

Author(s):

Mei Wei, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer, as demonstrated in the DESTINY-Breast01 trial.

Mei Wei, MD, an internal medicine specialist at University of Utah Health, discusses the efficacy of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive breast cancer, as demonstrated in the phase 2 DESTINY-Breast01 trial (NCT03248492).

A significant progression-free survival benefit was observed with the antibody-drug conjugate in the heavily pretreated patient population, Wei says. Additionally, the agent showed promise in patients who with brain metastases, Wei notes.

Importantly, in patients who had received previous treatment for their brain metastases, the median overall survival had not yet been reached, Wei concludes.

Related Videos
Ruth M. O’Regan, MD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Sheldon M. Feldman, MD
Dana Zakalik, MD
Alberto Montero, MD, MBA, CPHQ
Jairam Krishnamurthy, MD, FACP
Deena Mary Atieh Graham, MD
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.